Search the Newsreel

InspireMD Reports $1.77 Million Q2 Revenue and $14.32 Million Net Loss

InspireMD (NSPR) recall turns U.S. sales negative — and deepens quarterly loss

NSPR Rallies After Hours On FDA Green Light for Key Stroke-Prevention Trial Despite Withdrawn Annual Guidance

InspireMD, Inc. (NSPR) Reports Q2 Loss, Beats Revenue Estimates

InspireMD, Inc. (NSPR) reported a Q2 loss of $0.17 per share, outperforming the Zacks Consensus Estimate of a $0.2 loss and representing a 15% earnings surprise. The company's revenues for the quarter were $1.77 million, surpassing estimates by 7.33%, although slightly down from the …

INSPIREMD Q2 2026 Earnings Preview: Recent $NSPR Insider Trading, Hedge Fund Activity, and More

INSPIREMD (NSPR) is set to release its Q2 2026 earnings on August 17th, with analysts forecasting revenue of $1.41 million and a loss of $0.20 per share. Recent insider trading shows more purchases than sales, while hedge fund activity indicates both increased and decreased …

InspireMD (NSPR) grows revenue 56% but flags going concern and Nasdaq risk

InspireMD, Inc. reported increased revenues for the first half of 2026, up 56.3% to $5.17 million, driven by U.S. CGuard Prime sales and international growth, despite a voluntary recall of CGuard Prime impacting quarterly revenue and gross margin. The company posted a significant net …

InspireMD Q2 Results: Second Quarter 2026 Earnings Release Date Set

InspireMD, Inc. will release its second quarter 2026 financial results on August 17, 2026, followed by a conference call and webcast at 8:30 a.m. ET. The company, known for its CGuard Prime carotid stent system, will discuss its financial performance and operational updates, including …

InspireMD Schedules 8:30 a.m. Call to Discuss Q2 Results

InspireMD (Nasdaq: NSPR) announced it will release its second quarter 2026 financial results on Monday, August 17, 2026. The company will host a conference call and live audio webcast at 8:30 a.m. Eastern Time to discuss the results and recent highlights. Investors can participate …

Insider Buyers At InspireMD Recover Some Losses, But Still Down US$161k

Insiders at InspireMD bought US$420.8k worth of stock over the last year, but despite a recent 14% stock gain, they are still down US$161k on their purchases. While there was some insider selling, the net insider activity over the year indicates more buying than …

InspireMD Approves 221,666 Restricted Shares for New Hire

InspireMD (Nasdaq: NSPR) has granted 221,666 restricted shares to a new non-executive employee as an inducement for employment, in accordance with Nasdaq Listing Rule 5635(c)(4). These shares, granted under the company's 2024 Inducement Plan with a grant date of August 3, 2026, will vest …

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

InspireMD, Inc. announced that its Compensation Committee approved inducement grants totaling 221,666 shares of restricted stock to a new non-executive employee. These grants were made outside of the company's 2021 Equity Incentive Plan but under its 2024 Inducement Plan, in accordance with Nasdaq Listing …

InspireMD Inc (NSPR) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for InspireMD Inc (NSPR), detailing its current earnings forecast score, average price target from analysts, and a comparison with peers. It highlights expected revenue, EPS for past and upcoming quarters, and the overall analyst rating, which leans towards …

NSPR|InspireMD Inc|Price:0.654|Chg%:-0.018

This article provides a comprehensive stock analysis of InspireMD Inc (NSPR) by TradingKey, assigning it a "relatively very healthy" fundamental score and high growth potential, though its valuation is deemed "fairly valued." Key insights include high institutional ownership, multiple "Buy" ratings from analysts with …

InspireMD Eliminates Chief Commercial Officer Position

InspireMD has eliminated the position of Chief Commercial Officer, effective July 31, 2026, with Shane Gleason's employment ending on that date. This change signals a potential shift in the company's commercial strategy or organizational priorities. While the most recent analyst rating is a Buy …

InspireMD appoints Kathleen Kennedy as SVP of global sales By Investing.com

InspireMD, Inc. has appointed Kathleen Kennedy as Senior Vice President of Global Sales and Marketing. Kennedy, who previously served as Sales Director for InspireMD, brings over 30 years of medical device sales leadership experience and will report to CEO Marvin Slosman. Her appointment aligns …

InspireMD Inc.: InspireMD Appoints Carotid Intervention Commercial Leader Kathleen Kennedy as Senior Vice President of Global Sales and Marketing

InspireMD, Inc. has announced the appointment of Kathleen Kennedy as Senior Vice President of Global Sales and Marketing. Kennedy, with over 30 years of medical device sales leadership experience, including in carotid intervention, will report to CEO Marvin Slosman. Her role will be crucial …

Medical-device sales leader with more than 30 years returns to InspireMD

InspireMD (Nasdaq: NSPR) has appointed Kathleen Kennedy as Senior Vice President of Global Sales and Marketing. Kennedy, with over 30 years of medical device sales leadership, previously supported the U.S. launch of CGuard Prime and returns to help prepare for its potential U.S. commercial …

InspireMD Inc (NSPR) Institutional Confidence

InspireMD Inc (NSPR) has an institutional shareholding score of 3.00, placing it 130th out of 199 in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion is 49.38%, marking a 9.65% decrease quarter-over-quarter. James Simons is the largest institutional shareholder with 32.63K shares, …

NSPR|InspireMD Inc|Price:0.694|Chg%:+0.010

This article provides a detailed company profile for InspireMD Inc (NSPR), a medical device company specializing in MicroNet stent platform technology for vascular and coronary disease treatment. It covers the company's business scope, financial data, market performance, executive team, and institutional shareholding. The key …

InspireMD Inc (NSPR) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of InspireMD Inc (NSPR), listing its major shareholders and their respective proportions. It also provides a breakdown of shareholder types and institutional holdings over several quarters, along with recent changes in individual institutional holdings.

InspireMD Inc (NSPR) Cash Flow

This article provides a detailed cash flow statement for InspireMD Inc (NSPR), presenting quarterly and annual data for operating, investing, and financing activities over several years. It includes key figures such as operating cash flow, net income from continuing operations, capital expenditures, and free …

InspireMD Inc. Revenue Breakdown – NASDAQ:NSPR

InspireMD Inc. (NASDAQ: NSPR) generated $8.98 million USD in revenue last year, primarily from its CGuard Carotid Embolic Prevention System segment, which also brought in $8.98 million USD. The company's "Other" segment contributed $4.06 million USD to its revenue. This indicates a significant portion …

InspireMD Receives Nasdaq Minimum Bid Price Warning

InspireMD Inc. announced it has received a warning from Nasdaq regarding non-compliance with the minimum bid price rule. The company now has a 180-day grace period, until January 20, 2027, to regain compliance by having its common stock close at $1.00 or more for …

InspireMD Inc (NSPR) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis for InspireMD Inc (NSPR), noting its current valuation score is 7.68, ranking 136 out of 200 in its industry. It highlights the company's P/E ratio of -0.99, which is significantly below its recent high and above its recent …

InspireMD Disclosed Failure to Satisfy a Continued Listing Rule or Standard

InspireMD (NSPR) received a notice from Nasdaq on July 17, 2026, indicating its failure to meet the minimum bid price requirement of $1.00 for 30 consecutive business days. The company has 180 days, until January 13, 2027, to regain compliance while its stock continues …

InspireMD (NSPR) warned by Nasdaq over $1.00 bid price and delisting risk

InspireMD, Inc. (NSPR) received a notice from Nasdaq on July 17, 2026, indicating non-compliance with the minimum $1.00 bid price requirement. The company has 180 calendar days, until January 13, 2027, to regain compliance by achieving a closing bid price of at least $1.00 …

InspireMD gets Nasdaq notice for failing $1 minimum bid price rule

InspireMD (NSPR) received a Nasdaq notice on July 17, 2026, for failing to maintain the minimum $1 bid price, based on closing prices from June 3 to July 16. The company has until January 13, 2027, to regain compliance by achieving a $1 or …

InspireMD Inc. (NSPR) Gains Momentum: Breaking Above Key Support - Market Leader Picks

InspireMD Inc. (NSPR) Q1 2026 Earnings: Narrower Loss Than Expected But Shares Slide - Return On Capital

InspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue Estimates

Earnings call transcript: InspireMD beats Q1 2026 forecasts but faces operational pause

InspireMD Reports 53% Year-Over-Year Unit Sales Growth Amid Anticipated FDA Approvals and Voluntary Recall of CGuard Prime 135 cm Delivery System | NSPR Stock News

INSPIREMD ($NSPR) Releases Q4 2025 Earnings